Several strategies are being investigated to target MDSCs in cancer therapy. These include:
Inhibiting MDSC recruitment: Strategies to block the recruitment of MDSCs to the tumor site by targeting chemokine receptors like CCR2 and CXCR2. Depleting MDSCs: Use of cytotoxic agents or antibodies that specifically deplete MDSC populations. Differentiating MDSCs: Promoting the differentiation of MDSCs into mature myeloid cells that lack immunosuppressive functions. Inhibiting MDSC function: Targeting the metabolic pathways and enzymes (like arginase and inducible nitric oxide synthase) that are critical for MDSC immunosuppressive activity.
